Clinical trials: Active Population
Venous Thromboembolism
Dose-confirmatory Bridging Study in Total Hip Replacement
The objective of this dose-confirmatory bridging study is to investigate the safety and efficacy of rivaroxaban 5 to 10 mg once-daily (od) dosing in the prevention of venous thromboembolism (VTE) in Japanese patients undergoing…
- Trial name
- NCT01205932
- Testing
- Rivaroxaban (BAY59-7939), Enoxaparin
- Where
- 41 sites in Japan
- Volunteers
- 402 people
- Sponsor
- Bayer
Rheumatoid Arthritis
Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo and Adalimumab, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease
The purpose of this study was to determine how effective and safe the study drug Olokizumab was in patients with Rheumatoid Arthritis (RA) who had been already receiving but not fully responding to treatment with methotrexate…
- Trial name
- CREDO 2 (NCT02760407)
- Testing
- Olokizumab 64mg q4w, Olokizumab 64mg q2w, Adalimumab 40mg q2w
- Where
- 203 sites in United States, Argentina and 16 more
- Volunteers
- 1,648 people
- Sponsor
- R-Pharm International, LLC
Open-angle Glaucoma, Ocular Hypertension
A Phase IIb Safety and Efficacy Study of DE-126 Ophthalmic Solution in Primary Open-Angle Glaucoma or Ocular Hypertension- Angel Study
Treatment of elevated pressure in the eye (Intraocular pressure, or 'IOP') with eye drop medications has been shown to be effective in delaying or preventing the progression of glaucoma, and it is the only proven method for…
- Trial name
- NCT03216902
- Testing
- Vehicle of DE-126 Ophthalmic Solution, high dose of DE-126 Ophthalmic Solution, Topical ultra-low dose of DE-126 Ophthalmic Solution, Topical low dose of DE-126 Ophthalmic Solution
- Where
- 17 sites in United States, Japan
- Volunteers
- 241 people
- Sponsor
- Santen Inc.
Osteoarthritis
A Study to Assess Etoricoxib Versus Diclofenac in Chinese Patients With Osteoarthritis of the Knee or Hip (0663-080)(COMPLETED)
A Study to Assess Etoricoxib versus Diclofenac in Chinese Patients with Osteoarthritis of the Knee or Hip
- Trial name
- NCT00140972
- Testing
- MK0663; etoricoxib / Duration of Treatment:4 Weeks, Comparator: diclofenac sodium tablet 75 mg / Duration of Treatment:4 Weeks
- Volunteers
- 160 people
- Sponsor
- Organon and Co
Anesthesia, Local
A Study of Safety and the Local Anesthetic Effect of AG-920 Ophthalmic Solution in a Pediatric Population
A Phase 3, randomized, active-controlled, study in pediatric subjects. It is designed to evaluate the safety and anesthetic efficacy of one dose of AG-920 ophthalmic solution compared to Proparacaine Hydrochloride Ophthalmic…
- Trial name
- NCT05325853
- Testing
- AG-920, Proparacaine Ophthalmic
- Where
- United States
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- American Genomics, LLC
Anaemia
Evaluation of Dose Response Relationship, Safety and Efficacy of GSK1278863 in Hemodialysis-dependent Subjects With Chronic Kidney Disease Associated Anemia
This study is intended to evaluate the dose-response relationship of GSK1278863 over the first 4 weeks of treatment and evaluate the safety and efficacy of GSK1278863 over 24 weeks to maintain hemoglobin (Hgb) level in…
- Trial name
- NCT01977482
- Testing
- GSK1278863, rhEPO
- Where
- 107 sites in United States, Australia and 14 more
- Volunteers
- 216 people
- Sponsor
- GlaxoSmithKline
Type 2 Diabetes Mellitus
Phase III Trial to Evaluate the Efficacy and Safety of Initial Combination Therapy With Gemigliptin 50mg q.d and Metformin q.d
The objective of this study is to evaluate efficacy and safety of initial combination therapy with Gemigliptin 50mg q.d and Metformin q.d compared with either monotherapy in treatment naïve patients with type 2 diabetes, In other…
- Trial name
- NCT01787396
- Testing
- Gemigliptin 50mg, Metformin
- Where
- South Korea
- Volunteers
- 433 people
- Sponsor
- LG Life Sciences
Heart Failure
A Proof of Concept and Dose-finding Study of XXB750 in Patients With Heart Failure
This was a multicenter, randomized, placebo- and active-controlled, parallel-group, 24-week trial to investigate the efficacy, safety, and tolerability of XXB750 in participants with HFrEF/HFmrEF.
- Trial name
- NCT06142383
- Testing
- XXB750 Low dose, XXB750 Medium Dose, XXB750 High Dose
- Where
- 62 sites in United States, Bulgaria and 10 more
- Volunteers
- 136 people
- Sponsor
- Novartis Pharmaceuticals
Proctitis, Ulcerative
Efficacy and Safety Study of MAX-002 Suppository Versus Placebo and Active Medicine in Mild to Moderate Ulcerative Proctitis
This is a prospective, multicenter, double-blind (DB), controlled, randomized, parallel group comparison Phase 3a study to evaluate the efficacy and safety of new mesalamine suppositories (MAX-002) as compared to placebo and…
- Trial name
- NCT01016262
- Testing
- MAX-002, Canasa®
- Where
- 40 sites in United States, Canada and 1 more
- Volunteers
- 119 people
- Sponsor
- Forest Laboratories
Osteo Arthritis Knee
A Study to Evaluate the Analgesic Efficacy and Safety of V120083 in Subjects With Osteoarthritis (OA) of the Knee
The purpose of this study is to evaluate the analgesic efficacy of V120083 twice daily compared to placebo in subjects with moderate to severe chronic pain due to OA of the knee.
- Trial name
- NCT03028870
- Testing
- V120083, Naproxen
- Where
- 30 sites in United States
- Volunteers
- 291 people
- Sponsor
- Purdue Pharma LP
Lupus Nephritis
A Study of Guselkumab in Participants With Active Lupus Nephritis
The purpose of this study is to evaluate the efficacy of guselkumab in participants with active lupus nephritis (LN).
- Trial name
- ORCHID-LN (NCT04376827)
- Testing
- Guselkumab Dose 1, Guselkumab Dose 2, Standard-of-care treatment
- Where
- 60 sites in United States, Argentina and 7 more
- Volunteers
- 33 people
- Sponsor
- Janssen Research & Development, LLC
Heart Failure
Effects of Aliskiren, Ramipril, and the Combination on Levels of Angiotensin II in Patients With Decompensated Systolic Heart Failure
In addition to the blood pressure lowering effects of aliskiren, it may have beneficial effects on blocking the so called RAAS (renin-angiotensin-aldosterone system) at the tissue level.
- Trial name
- ESCAPE-SHF (NCT00923156)
- Testing
- aliskiren, ramipril
- Where
- 16 sites in Germany, Poland and 1 more
- Volunteers
- 123 people
- Sponsor
- Novartis Pharmaceuticals
Diabetes Mellitus, Type 2
Efficacy and Safety of Albiglutide in Treatment of Type 2 Diabetes
The purpose of this study is to determine if albiglutide is safe and effective in the treatment of type 2 diabetes.
- Trial name
- NCT00838903
- Testing
- albiglutide, sitagliptin, glimepiride
- Where
- 386 sites in United States, Albania and 9 more
- Volunteers
- 1,049 people
- Sponsor
- GlaxoSmithKline
Ulcerative Colitis Chronic Moderate, Ulcerative Colitis Chronic Severe
PN-943 in Adults With Moderate to Severe Active Ulcerative Colitis (UC)
The purpose of the study is to evaluate the safety, tolerability, and clinical efficacy of PN-943 450 mg twice daily [BID] and PN-943 150 mg BID, compared with placebo BID, in subjects with moderate to severe active Ulcerative…
- Trial name
- NCT04504383
- Testing
- PN-943
- Where
- 122 sites in United States, Austria and 11 more
- Volunteers
- 169 people
- Sponsor
- Protagonist Therapeutics, Inc.
Osteoarthritis of the Knee
Apitox, Honeybee Toxin for Pain and Inflammation of Osteoarthritis
The study will identify the efficacy of Apitox, purified honeybee toxin, in 330 patients with diagnosed osteoarthritis of the knee.
- Trial name
- NCT01112722
- Testing
- Apitox, purified honeybee toxin, lyophilized in saline, histamine
- Where
- 15 sites in United States
- Volunteers
- 363 people
- Sponsor
- Apimeds, Inc.
Osteoarthritis, Knee, Knee Osteoarthritis
2 Weekly Intra-articular Hyaluronan Knee Injections, Given 1 wk. Apart, of HYMOVIS Combined With Physical Exercise Program (PEP) Compared to PEP Alone, in Relatively Young, Active Population of Subjects With Patellofemoral Osteoarthritis (PFOA) and/or Tibiofemoral Osteoarthritis (TFOA)
Knee osteoarthritis (OA) is among the most common causes of musculoskeletal pain and disability. At present, there is no cure for OA.
- Conditions
- Osteoarthritis, Knee, Knee Osteoarthritis, Patellofemoral Osteoarthritis
- Trial name
- NCT03281837
- Testing
- HYMOVIS plus Physical Exercise Program (PEP), Physical Exercise Program (PEP) alone
- Where
- 10 sites in United States
- Volunteers
- 148 people
- Sponsor
- Fidia Pharma USA Inc.
Adult Growth Hormone Deficiency
A Safety, Pharmacokinetic and Pharmacodynamic Study of ACP-001 (TransCon hGH) in Adults With Growth Hormone Deficiency
This study investigates the safety, tolerability, pharmacokinetic profile (PK), and pharmacodynamic response (PD) of three different doses of ACP-001 given once-a-week compared to one dose-level of an approved daily human growth…
- Trial name
- NCT01247675
- Testing
- ACP-001 (TransCon hGH), Omnitrope
- Where
- 4 sites in Denmark, Germany and 2 more
- Volunteers
- 37 people
- Sponsor
- Ascendis Pharma A/S
Type 2 Diabetes Mellitus
Phase 2b Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Assess the PD Response and Safety of Three Dose Levels of (PB1023) Injection Following 20 Weeks of Weekly SC Dosing in Adults With T2DM
Primary objective: The primary objective of this study is to define the dose response of Glymera as measured as the change from baseline in hemoglobin A1c (HbA1c) following 20 weeks of once-weekly dosing.
- Trial name
- NCT01658501
- Testing
- 50 mg PB1023, 70 mg PB1023, 100 mg PB1023
- Where
- 93 sites in United States
- Volunteers
- 593 people
- Sponsor
- PhaseBio Pharmaceuticals Inc.
Chronic Kidney Disease Requiring Chronic Dialysis
A Phase 3 Study to Investigate the Safety and Efficacy of PA21, a Phosphate Binder, in Dialysis Patients
This is a Phase 3, randomised, active controlled, multicentre study to investigate the safety and efficacy of PA21, a phosphate binder, for control of hyperphosphataemia in dialysis patients.
- Trial name
- NCT01324128
- Testing
- PA21 (2.5 g tablet containing 500 mg iron), Sevelamer carbonate, PA21-1 (1.25 g tablet containing 250 mg iron)
- Where
- 15 sites in United States, Austria and 13 more
- Volunteers
- 1,059 people
- Sponsor
- Vifor Pharma
Hypertension
Blood Pressure Lowering of Aliskiren HCTZ Compared to HCTZ in Stage 2 Systolic Hypertension in Older Population
The purpose of the study is to evaluate the efficacy and safety of initial use of a fixed dose combination of aliskiren Hydrochlorothiazide (HCTZ) compared to Hydrochlorothiazide in older population with Stage 2 systolic…
- Trial name
- ACTION (NCT00760266)
- Testing
- Aliskiren, Hydrochlorothiazide
- Where
- United States
- Volunteers
- 451 people
- Sponsor
- Novartis
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.